Drugs / Epofolate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00546247 | Jan 2008 → Mar 2010 | cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/2 | NCT00550017 | Dec 2007 → Mar 2010 | cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epofolate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00550017 ↗ |
| Known as | BMS-753493 | “The purpose of this clinical research study is to study the safety of Epofolate (BMS-753493) in patients with advanced cancers” NCT00546247 ↗1“Epofolate (BMS-753493)” NCT00550017 ↗ |
| Route | Intravenous | “Intravenous solution, intravenous” NCT00546247 ↗ |